Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

SRF fusion oncogenes encode constitutively activated chimeric transcription factors in myoid soft tissue tumors [MSC_hTERT]

ABSTRACT: SRF fusion genes result from chromosomal translocations in muscle-related soft tissue tumors, including perivascular tumors, myofibroma and rhabdomyosarcoma. SRF encodes the Serum Response Factor, a well-characterized transcription factor that dimerizes and associates with the cofactors TCF or MRTF to regulate muscle development. Here, we characterized four SRF fusion genes: SRF::RELA, SRF::FOXO1, SRF::ICA1L and SRF::PDGFRB. All fusions proteins were nuclear and dimerized through the SRF MADS box. SRF::RELA, SRF::FOXO1, and SRF::ICA1L acted as constitutively active transcription factors, independently of canonical cofactors. Their activity depended on the DNA-binding MADS box of SRF and the transactivation domain of the partner protein. We identified a cryptic transactivation domain within cytosolic ICA1L. These three SRF fusions promoted mesenchymal cell proliferation and upregulated muscle-related genes. They are representative of 98% of the identified SRF fusion cases. In contrast, SRF::PDGFRB activity relied on the tyrosine kinase domain and was sensitive to imatinib. SRF::PDGFRB acted as an oncogene in Ba/F3 cells, activated STAT1 signaling, and induced an interferon-like inflammatory response, in line with the inflammatory myofibroblastic tumor, in which that fusion was identified. In conclusion, SRF fusions constitute a novel family of oncogenes supporting cell proliferation and expression of muscle differentiation markers in myoid soft tissue tumors.

ORGANISM(S): Homo sapiens

PROVIDER: GSE303260 | GEO | 2026/07/18

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

SRF fusion oncogenes encode constitutively activated chimeric transcription factors in myoid soft tissue tumors [C2C12]

Project description:SRF fusion genes result from chromosomal translocations in muscle-related soft tissue tumors, including perivascular tumors, myofibroma and rhabdomyosarcoma. SRF encodes the Serum Response Factor, a well-characterized transcription factor that dimerizes and associates with the cofactors TCF or MRTF to regulate muscle development. Here, we characterized four SRF fusion genes: SRF::RELA, SRF::FOXO1, SRF::ICA1L and SRF::PDGFRB. All fusions proteins were nuclear and dimerized through the SRF MADS box. SRF::RELA, SRF::FOXO1, and SRF::ICA1L acted as constitutively active transcription factors, independently of canonical cofactors. Their activity depended on the DNA-binding MADS box of SRF and the transactivation domain of the partner protein. We identified a cryptic transactivation domain within cytosolic ICA1L. These three SRF fusions promoted mesenchymal cell proliferation and upregulated muscle-related genes. They are representative of 98% of the identified SRF fusion cases. In contrast, SRF::PDGFRB activity relied on the tyrosine kinase domain and was sensitive to imatinib. SRF::PDGFRB acted as an oncogene in Ba/F3 cells, activated STAT1 signaling, and induced an interferon-like inflammatory response, in line with the inflammatory myofibroblastic tumor, in which that fusion was identified. In conclusion, SRF fusions constitute a novel family of oncogenes supporting cell proliferation and expression of muscle differentiation markers in myoid soft tissue tumors.

2026-07-18 | GSE303259 | GEO

PdgfrB signaling impairs skeletal muscle regeneration

Project description:Genetically deleting PdgfrB in mature myocytes enhances skeletal muscle regeneration and fusion capability whereas activating PdgfrB inhibits it.

2024-10-15 | GSE279532 | GEO

The influence of the deletion of Serum Response Factor in B cells

Project description:Serum response factor (SRF), a MADS-box transcription factor, is essential for murine embryonic development and for the function of muscle cells and neurons. SRF and its transcriptional co-factors are broadly expressed. To determine the in vivo role of SRF in developing lymphocytes we specifically inactivated the murine Srf gene during T or B cell development using lymphocyte-specific Cre transgenic mouse lines. T cell-specific Srf deletion led to a severe block in thymocyte development at the transition from double to single positive stage. The few residual T cells detectable in the periphery retained at least one functional Srf allele, thereby demonstrating the importance of SRF in T cell development. In contrast, deletion of Srf in developing B cells did not interfere with the growth and survival of B cells in general, yet led to a complete loss of marginal zone B cells and a marked reduction of the CD5+ B cell subset. Our study also revealed a contribution of SRF to the expression of the surface molecules IgM, CD19, and the chemokine receptor 4 in B lymphocytes. Keywords: Genetic modification

2007-06-27 | GSE7412 | GEO

Transcription profiling of mouse IgM+IgD+ cells and srf-deficient IgM+IgD+ cells isolated from spleens to investigate the role of serum response factor

2008-06-15 | E-GEOD-7412 | biostudies-arrayexpress

ZFTA–RELA ependymomas make itaconate to epigenetically drive fusion expression [ChIP-Seq]

Project description:ZFTA-RELA ependymomas are malignant brain tumors that are frequently lethal. They are defined by fusions formed between the putative chromatin remodeler ZFTA and the NFkB-mediator-RELA. We identified that ZFTA-RELA cells produced itaconate, a key macrophage-associated immunomodulator metabolite. However, itaconate production by tumor cells and its tumor-intrinsic role are not well-established. Itaconate is synthesized by the enzyme Aconitate Decarboxylase-1 (ACOD1) and the ZFTA-RELA fusion upregulated ACOD1 in an NFkB-dependent manner. Additionally, itaconate production enabled a feed-forward system that maintained pathogenic ZFTA-RELA fusion expression through epigenetic activation. To supply the metabolic fuel needed to generate itaconate, these tumors epigenetically activated PI3K/mTOR signaling to enhance glutaminolysis, which provided the carbons necessary for itaconate synthesis. Consequently, antagonizing glutamine metabolism lowered pathogenic ZFTA-RELA levels and was potently therapeutic in multiple in vivo models. Finally, combining glutamine antagonism with PI3K/mTOR inhibition abrogated spinal metastasis. Our data demonstrate that ZFTA-RELA ependymomas subvert a macrophage-like itaconate metabolic pathway to maintain expression of the ZFTA-RELA fusion driver, implicating itaconate as an oncometabolite. Taken together, our results position itaconate upregulation as a previously unappreciated driver of ZFTA-RELA ependymomas. This study therefore has implications for future drug development for children with this devastating brain tumor and will further our understanding of oncometabolites as a novel class of therapeutic dependencies in cancers.

2025-11-17 | GSE294955 | GEO

ZFTA–RELA ependymomas make itaconate to epigenetically drive fusion expression [ATAC-Seq]

2025-11-17 | GSE294954 | GEO

PF4-Cre mediated deletion of SRF in murine megakaryocytes.

Project description:Srf is a MADS-box transcription factor that is critical for muscle differentiation. Its function in hematopoiesis has not yet been revealed. Mkl1, a cofactor of Srf, is part of the t(1;22) translocation in acute megakaryoblastic leukemia, and plays a critical role in megakaryopoiesis. In order to test the role of Srf in megakaryocyte development, we crossed Pf4-Cre mice, which express Cre recombinase in cells committed to the megakaryocytic lineage, to SrfF/F mice in which functional Srf is no longer expressed after Cre-mediated excision. Pf4-Cre/SrfF/F (KO) mice are born with normal mendelian frequency, but have significant macrothrombocytopenia with approximately 50% reduction in platelet count. In contrast, the BM has increased numbers and percentages of CD41+ megakaryocytes (WT: 0.41+/-0.06%; KO: 1.92+/-0.12%) with significantly reduced ploidy. KO mice show significantly increased megakaryocyte progenitors in the BM by both FACS analysis and CFU-Mk. Megakaryocytes lacking Srf have abnormal stress fiber and demarcation membrane formation and platelets lacking Srf have abnormal actin distribution. In vitro and in vivo assays reveal platelet function defects in KO mice. Critical actin cytoskeletal genes are downregulated in KO megakaryocytes. Thus, Srf is required for normal megakaryocyte maturation and platelet production, due at least in part, to regulation of cytoskeletal genes. C-kit+CD41+ megakaryocyte progenitors from PF4-Cre/SRF C57BL/6 SRF WT (3) and C57BL/6 SRF KO (3) mice were sorted by flow cytometry and cultured for three days in thrombopoietin.

2010-07-13 | E-GEOD-21859 | biostudies-arrayexpress

PF4-Cre mediated deletion of SRF in murine megakaryocytes.

2010-07-13 | GSE21859 | GEO

SRF is a new player in 3D genome organization and stem cell pluripotency

Project description:Serum response factor (SRF) is a transcription factor essential for cell proliferation, differentiation, and migration, and is required for primitive streak and mesoderm formation in the embryo. The canonical roles of SRF are mediated by a diverse set of context-dependent cofactors. Here we show that SRF physically interacts with CTCF and cohesin subunits at TAD boundaries and loop anchors. SRF reinforces the insulation of TADs and promotes the formation of long-range chromatin loops. In ES cells, SRF associates with Oct4, Sox2, and Nanog and contributes to the formation of 3D pluripotency hubs. Our findings reveal new roles of SRF in higher-order chromatin organization.

2024-10-14 | PXD049365 | Pride

Differential regulation of cranial and cardiac neural crest by Serum Response Factor

Project description:The goal of this experiment was to identify genes regulated by Serum Response Factor (SRF) in the neural crest in the craniofacial region, including whether there were different targets in different craniofacial prominences. SRF is an essential transcription factor that influences many cellular processes including cell proliferation, migration, and differentiation. SRF directly regulates and is required for immediate early gene (IEG) and actin cytoskeleton-related gene expression. SRF coordinates these competing transcription programs through discrete sets of cofactors, the Ternary Complex Factors (TCFs) and Myocardin Related Transcription Factors (MRTFs). The relative contribution of these two programs to in vivo SRF activity and mutant phenotypes is not fully understood. To study how SRF utilizes its cofactors during development, we generated a knock-in SrfaI allele in mice harboring point mutations that disrupt SRF-MRTF-DNA complex formation but leave SRF-TCF activity unaffected. Homozygous SrfaI/aI mutants die at E10.5 with notable cardiovascular phenotypes, and neural crest conditional mutants succumb at birth to defects of the cardiac outflow tract but display none of the craniofacial phenotypes associated with complete loss of SRF in that lineage.

2021-10-30 | GSE186770 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data